Keyphrases
Non-steroidal Anti-inflammatory Drugs (NSAIDs)
100%
National Cohort Study
100%
Cardiovascular Risk
100%
Rheumatoid Arthritis
100%
Rheumatoid Arthritis Patients
50%
Drug Use
30%
Cardiovascular Disease
20%
Associated Risk
20%
Drug Dependence
20%
Pharmacotherapy
10%
Longitudinal Cohort Study
10%
Survival Model
10%
Patient-centered
10%
Outpatient Care
10%
Pain Relief
10%
Combined Endpoints
10%
Disease-associated
10%
Rofecoxib
10%
Care Provision
10%
Adverse Effects
10%
Registry Data
10%
Stroke Mortality
10%
Risk Factors
10%
Diclofenac
10%
Cardiovascular Mortality
10%
Non-rheumatoid
10%
Risk Increase
10%
Myocardial Infarction Mortality
10%
Multivariable
10%
Inpatient Care
10%
Significant Risk Factors
10%
Cardiovascular Outcomes
10%
Medicine and Dentistry
Cardiovascular Disease
100%
Inflammatory Arthritis
100%
Nonsteroid Antiinflammatory Agent
100%
Rheumatoid Arthritis
100%
Cohort Analysis
100%
Cardiovascular Risk
40%
Drug Use
30%
Drug Therapy
10%
Adverse Effect
10%
Cardiovascular Mortality
10%
Myocardial Infarction
10%
Cardiovascular System
10%
Apoplexy
10%
Analgesia
10%
Rofecoxib
10%
Diclofenac
10%
Health Care
10%
Outpatient
10%
Pharmacology, Toxicology and Pharmaceutical Science
Inflammatory Arthritis
100%
Non-Steroidal Anti-Inflammatory Drug
100%
Cardiovascular Disease
100%
Rheumatoid Arthritis
100%
Cohort Study
100%
Cardiovascular Risk
40%
Rofecoxib
10%
Cerebrovascular Accident
10%
Cardiovascular Mortality
10%
Heart Infarction
10%
Diclofenac
10%
Pharmacotherapy
10%
Biochemistry, Genetics and Molecular Biology
Cohort Study
100%
Rofecoxib
50%
Drug Therapy
50%
Cardiovascular Mortality
50%
Immunology and Microbiology
Inflammatory Arthritis
100%
Cardiovascular Mortality
12%
Drug Therapy
12%